8-K: Precigen Announces First Quarter 2024 Results and Key Clinical Milestones

Precigen reported its first quarter 2024 financial results and provided updates on its clinical programs, including the anticipated presentation of pivotal Phase 2 data for PRGN-2012 at the ASCO Annual Meeting.

Summary

• Precigen announced its first quarter 2024 financial results, highlighting a cash balance of $44.8 million as of March 31, 2024.
• The company is preparing for a potential commercial launch of PRGN-2012 in 2025, with a rolling BLA submission anticipated in the second half of 2024.
• Research and development expenses increased by 17% to $14.2 million, while selling, general, and administrative expenses decreased by 13% to $10.1 million compared to the same period last year.
• Total revenues decreased by 43% to $1.1 million, primarily due to reduced activity at Exemplar.
• The net loss for the quarter was $23.7 million, or $(0.10) per share, consistent with the net loss of $22.7 million in the same period last year.
• The company is actively evaluating financing opportunities to strengthen its balance sheet.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical progress and some financial challenges. The positive clinical data for PRGN-2012 and the upcoming BLA submission are encouraging, but the decrease in revenue and the need for potential financing raise some concerns. Overall, the sentiment is cautiously optimistic.

Positives

• PRGN-2012 has shown promising clinical results with a 50% complete response rate and durable responses.
• The FDA has confirmed that the ongoing Phase 1/2 study will serve as pivotal, eliminating the need for an additional randomized, placebo-controlled trial.
• The company is on track for a rolling BLA submission for PRGN-2012 in the second half of 2024.
• Commercial readiness activities are underway for a potential launch of PRGN-2012 in 2025.
• SG&A expenses decreased by 13%, indicating improved cost management.
• The company has a strong cash position of $44.8 million.

Negatives

• Total revenues decreased by 43% compared to the same period last year.
• Gross margin on products and services declined due to decreased revenues at Exemplar.
• Research and development expenses increased by 17%, which may impact profitability.
• The company reported a net loss of $23.7 million for the quarter.

Risks

• The company is evaluating various financing opportunities to strengthen its balance sheet, which may indicate a need for additional capital.
• The decrease in revenue and gross margin could impact the company's financial stability.
• The increase in R&D expenses may put pressure on the company's profitability.
• The success of PRGN-2012 is critical for the company's future, and any setbacks could have a significant impact.

Future Outlook

The company anticipates a rolling BLA submission for PRGN-2012 in the second half of 2024 and is preparing for a potential commercial launch in 2025. They are also evaluating financing opportunities to strengthen their balance sheet.

Management Comments

• We are excited to share the pivotal Phase 2 data for our PRGN-2012 study in patients with RRP at ASCO and look forward to providing additional details regarding the results at our planned conference call following the presentation, said Helen Sabzevari, PhD, President and CEO of Precigen.
• We remain on track for a PRGN-2012 rolling BLA submission in the second half of 2024 and we are actively moving ahead with our commercial readiness efforts in anticipation of a potential launch of PRGN-2012 in 2025, said Helen Sabzevari, PhD, President and CEO of Precigen.
• Based on the competitive advantages of PRGN-2012, including a favorable route of administration, safety profile and the efficacy demonstrated in the clinical trial results so far, we believe, PRGN-2012 has the potential to be the first-in-class and best-in-class treatment for RRP patients, said Helen Sabzevari, PhD, President and CEO of Precigen.
• With multiple milestones anticipated in 2024 and 2025, we remain steadfastly committed to a strategy of sound financial management, said Harry Thomasian Jr., CFO of Precigen.
• We are evaluating various financing opportunities to strengthen our balance sheet as we prepare our lead asset, PRGN-2012, for potential commercial launch in 2025, said Harry Thomasian Jr., CFO of Precigen.

Industry Context

This announcement highlights Precigen's progress in the competitive gene and cell therapy space, particularly in the treatment of RRP and HPV-associated cancers. The company's focus on innovative platforms like AdenoVerse and UltraCAR-T positions it to potentially address unmet medical needs.

Comparison to Industry Standards

• The 50% complete response rate for PRGN-2012 in RRP is a strong result compared to existing treatments, which often involve repeated surgeries.
• The accelerated approval pathway and orphan drug designations for PRGN-2012 are positive indicators of regulatory support.
• The company's UltraCAR-T platform, with its overnight manufacturing process, aims to address limitations of traditional CAR-T therapies, such as long manufacturing times and high costs, which are common challenges for companies like Gilead (Yescarta) and Novartis (Kymriah).
• The focus on repeat dosing with the AdenoVerse platform is a differentiator compared to other viral vector-based gene therapies, which often face challenges with neutralizing antibodies, a problem that companies like BioMarin have had to address.
• The company's financial results show a decrease in revenue and an increase in R&D expenses, which is typical for a clinical-stage biotech company, but the company will need to manage its cash burn carefully, similar to other companies in the sector such as bluebird bio.

Stakeholder Impact

• Shareholders may be positively impacted by the clinical progress of PRGN-2012 and the potential for commercialization.
• Employees may benefit from the company's growth and development.
• Patients with RRP may have a new treatment option with PRGN-2012.
• Customers and suppliers may see increased activity as the company moves towards commercialization.

Next Steps

• The company will present pivotal Phase 2 data for PRGN-2012 at the ASCO Annual Meeting on June 3rd.
• A conference call will be held on June 3rd to discuss the PRGN-2012 study results and provide business updates.
• The company anticipates a rolling BLA submission for PRGN-2012 in the second half of 2024.
• Commercial readiness activities are underway for a potential PRGN-2012 launch in 2025.
• The company will co-sponsor the inaugural RRP Awareness Day on June 11th.
• An interim Phase 1b dose expansion data presentation for PRGN-3006 is anticipated in the second half of 2024.
• A preliminary Phase 1 dose escalation data presentation for PRGN-3007 is anticipated by the end of 2024.

Key Dates

Keywords

PRGN-2012, AdenoVerse, UltraCAR-T, RRP, gene therapy, cell therapy, biopharmaceutical, clinical trial, ASCO, BLA, HPV, immuno-oncology